Myeloid and Monocytic Leukemia, Phase I

A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BL-M11D1 in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients

Volunteers
Health Professionals

What is the purpose of this trial?

Ia: To observe the safety and tolerability of BL-M11D1 in patients with relapsed/refractory acute myeloid leukemia to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of BL-M11D1. Ib: Further observe the safety and tolerability of BL-M11D1 at the recommended dose in phase Ia to determine the recommended dose in phase II clinical study (RP2D).

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Farah Fasihuddin

farah.fasihuddin@yale.edu

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Amer Zeidan, MBBS
Professor of Internal Medicine (Hematology); Chief, Division of Hematologic Malignancies; Director, Early Therapeutics Research, Yale Cancer Center; Director, Leukemia and Myeloid Malignancies Program, Yale Cancer Center; Assistant Medical Director, Clinical Trials Office (CTO), Yale Cancer Center; Co-Leader, Leukemia and Myeloid Malignancies Clinical Research Team (CRT), Yale Cancer Center

Sub-Investigators

Last Updated
01/13/2026
Study HIC
#2000038377